Allaforte, 50 mg 10 pcs.

The active ingredient of the drug is bromine hydrogenate salt of lappaconitin alkaloid with accompanying alkaloids, derived from white bean hogweed herb or rhizomes and roots of white bean hogweed – Aconitum leucostomum Worosch, or from rhizomes with roots of northern wolfberry (high wolfberry) – Aconitum septentrionale Koelle (A. excelsum Reichenb.), family Ranunculaceae, or from technical alkaloids sum of the buttercup family.

Indications

ArrhythmiaEventricular and ventricular extrasystoles, paroxysmal forms of atrial fibrillation and flutter, paroxysmal supraventricular tachycardia, including in Wolf-Parkinson-White syndrome, paroxysmal ventricular tachycardia (in the absence of organic myocardial changes).

Active ingredient

Lappaconitine hydrobromide

Interaction

Inducers of microsomal liver enzymes do not affect the effectiveness of lappaconitine hydrobromide.

Directions for use

The drug should be started under a doctor’s supervision. Orally, after a meal, swallowing the tablet whole and drinking a small amount of water at room temperature. It is strictly forbidden to break, crush or chew the tablets!

Contraindications

Hypersensitivity to the drug components, sinoatrial block, grade II and III AV block (without artificial pacemaker), cardiogenic shock, right bundle branch block combined with left bundle branch block, severe arterial hypotension (systolic BP less than 90 mm Hg).), chronic heart failure III-IV functional class according to NYHA classification, significant left ventricular myocardial hypertrophy (≥1.4 cm), presence of postinfarction cardiosclerosis, acute coronary syndrome, Brugada syndrome, arrhythmogenic cardiomyopathy (dysplasia) of the right ventricle, severe hepatic and/or renal dysfunction, age under 18 years, lactose intolerance, lactase deficiency or glucose-galactose malabsorption, syndrome of prolonged or shortened QT interval, cardiac defects, arrhythmogenic effect of any antiarrhythmic drug in the history, pregnancy, breastfeeding, alcohol abuse, AV block of degree I with PQ interval prolongation more than 200 ms, dilated cardiomyopathy, restrictive cardiomyopathy, myocarditis, absence of antiarrhythmic effect during treatment with Allapinin drug in the history.

Side effects

According to the World Health Organization, adverse effects are classified according to their frequency of development as follows: very common (≥10% of appointments); common (≥1% and < 10%); infrequent (≥0.1% and < 1%); rare (≥0.01% and < 0.1%); very rare (< 0.01%); frequency unknown (not enough data to estimate frequency of development).

Overdose

The drug has a small therapeutic latitude, so severe intoxication can easily occur (especially with the simultaneous use of other antiarrhythmic agents).

Pregnancy use

Animal studies have shown that lappaconitine hydrobromide at doses of 1-5 mg/kg has no teratogenic and embryotoxic effects.

Similarities

Allapinin